Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANTX Stock Forecast 2026-2027
$4.67
Current Price
$168.20M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ANTX Price Targets
+92.7%
To High Target of $9.00
+92.7%
To Median Target of $9.00
+92.7%
To Low Target of $9.00
ANTX Price Momentum
+3.8%
1 Week Change
-4.7%
1 Month Change
+328.4%
1 Year Change
+309.6%
Year-to-Date Change
-32.4%
From 52W High of $6.91
+367.0%
From 52W Low of $1.00
📊 TOP ANALYST CALLS
Did ANTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AN2 Therapeutics is one of their latest high-conviction picks.
Latest ANTX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ANTX has a bullish consensus with a median price target of $9.00 (ranging from $9.00 to $9.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.67, the median forecast implies a 92.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Schwartz at Leerink Partners, projecting a 92.7% upside. Conversely, the most conservative target is provided by Joseph Schwartz at Leerink Partners, suggesting a 92.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANTX Analyst Ratings
1
Buy
0
Hold
0
Sell
ANTX Price Target Range
Low
$9.00
Average
$9.00
High
$9.00
Current: $4.67
Latest ANTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2026 | Leerink Partners | Joseph Schwartz | Outperform | Upgrade | $9.00 |
| May 5, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Mar 26, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Feb 25, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Feb 3, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Nov 19, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Nov 18, 2024 | TD Cowen | Hold | Downgrade | $N/A | |
| Aug 9, 2024 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jul 3, 2024 | Leerink Partners | Outperform | Upgrade | $N/A | |
| May 16, 2024 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Apr 2, 2024 | JMP Securities | Market Outperform | Upgrade | $N/A | |
| Apr 1, 2024 | Oppenheimer | Perform | Reiterates | $N/A | |
| Feb 13, 2024 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Feb 12, 2024 | Evercore ISI Group | In-Line | Downgrade | $N/A | |
| Feb 12, 2024 | Oppenheimer | Perform | Downgrade | $N/A | |
| Feb 12, 2024 | JMP Securities | Market Perform | Downgrade | $N/A | |
| Jan 4, 2024 | JMP Securities | Market Outperform | Initiates | $N/A | |
| Mar 30, 2023 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 14, 2022 | SVB Leerink | Outperform | Maintains | $N/A | |
| Apr 19, 2022 | Evercore ISI Group | Outperform | Initiates | $N/A |
AN2 Therapeutics, Inc. (ANTX) Competitors
The following stocks are similar to AN2 Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANTX
AN2 Therapeutics
mkt cap
162.07M
AN2 Therapeutics, Inc. (ANTX) Financial Data
AN2 Therapeutics, Inc. has a market capitalization of $168.20M with a P/E ratio of -4.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.6%.
Valuation Metrics
Market Cap
$168.20M
Enterprise Value
$86.15M
P/E Ratio
-4.0x
PEG Ratio
0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+50.7%
Current Ratio
15.7x
Debt/Equity
0.0x
ROE
-44.6%
ROA
-27.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AN2 Therapeutics, Inc. (ANTX) Business Model
About AN2 Therapeutics, Inc.
What They Do
Develops novel therapeutics for infectious diseases.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, generating revenue through the discovery and development of small molecule therapeutics derived from its proprietary boron chemistry platform. AN2 Therapeutics focuses on serious infectious diseases with significant unmet needs and aims to bring its drug candidates, like epetraborole and AN2-502998, through clinical trials and to market.
Additional Information
With a strong emphasis on global health initiatives, AN2 Therapeutics seeks to create transformative medicines that enhance patient outcomes for rare and chronic conditions. The company has strategic collaborations, including a partnership with GSK, to further its research and development efforts in the field of infectious diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Mr. Eric E. Easom
Country
United States
IPO Year
2022
Website
www.an2therapeutics.comAN2 Therapeutics, Inc. (ANTX) Latest News & Analysis
Latest News
The Healthcare M&A Wave
29 days ago
Quick Summary
This week's InnovationRx covers biotech mergers and acquisitions, highlights India's Anthem Biosciences, and offers additional insights. Subscription available for more updates.
Why It Matters
The focus on biotech M&A and emerging companies like Anthem Biosciences indicates potential investment opportunities and trends in a rapidly evolving sector.
Source: Forbes
Market Sentiment:
Neutral
Quick Summary
AN2 Therapeutics (Nasdaq: ANTX) reports positive results from studies on its oral CPSF3 inhibitor, AN2-502998, for treating chronic Chagas disease, supporting its development pipeline.
Why It Matters
Positive results from AN2 Therapeutics' studies on AN2-502998 for Chagas disease enhance the company's growth potential and attract investor interest in its innovative therapies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AN2 Therapeutics (Nasdaq: ANTX) will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET, with management available for one-on-one meetings.
Why It Matters
AN2 Therapeutics' presentation at a major healthcare conference signals potential developments in its drug pipeline, which could impact stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2 months ago
Quick Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX) reported Q1 2026 financial results, highlighting plans to enter Phase 2 development for a new program targeting polycythemia vera in Q3 2026.
Why It Matters
AN2 Therapeutics' advancement into Phase 2 development for polycythemia vera could signal potential revenue growth and increased valuation, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX) will participate in the Stifel Virtual Targeted Oncology Forum on May 19, 2026. CEO Eric Easom will speak, and management will hold 1x1 meetings. Webcast available online.
Why It Matters
AN2 Therapeutics' CEO's participation in a prominent oncology forum highlights company visibility and potential investor interest, impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AN2 Therapeutics (Nasdaq: ANTX) has begun a Phase 2 clinical trial for epetraborole, targeting pulmonary disease from Mycobacterium abscessus, focusing on safety and efficacy.
Why It Matters
The initiation of a Phase 2 clinical trial for epetraborole signals potential advancements in treatment options, which could enhance AN2 Therapeutics' market position and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ANTX Stock
What is AN2 Therapeutics, Inc.'s (ANTX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, AN2 Therapeutics, Inc. (ANTX) has a median price target of $9.00. The highest price target is $9.00 and the lowest is $9.00.
Is ANTX stock a good investment in 2027?
According to current analyst ratings, ANTX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANTX stock?
Wall Street analysts predict ANTX stock could reach $9.00 in the next 12 months. This represents a 92.7% increase from the current price of $4.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AN2 Therapeutics, Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, generating revenue through the discovery and development of small molecule therapeutics derived from its proprietary boron chemistry platform. AN2 Therapeutics focuses on serious infectious diseases with significant unmet needs and aims to bring its drug candidates, like epetraborole and AN2-502998, through clinical trials and to market.
What is the highest forecasted price for ANTX AN2 Therapeutics, Inc.?
The highest price target for ANTX is $9.00 from Joseph Schwartz at Leerink Partners, which represents a 92.7% increase from the current price of $4.67.
What is the lowest forecasted price for ANTX AN2 Therapeutics, Inc.?
The lowest price target for ANTX is $9.00 from Joseph Schwartz at Leerink Partners, which represents a 92.7% increase from the current price of $4.67.
What is the overall ANTX consensus from analysts for AN2 Therapeutics, Inc.?
The overall analyst consensus for ANTX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are ANTX stock price projections?
Stock price projections, including those for AN2 Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:06 AM UTC